24.11.2023 • News

Novo Nordisk to Invest €2.1 Billion in French Production Site

Novo Nordisk wants to make another major capital investment in production capacity for its diabetes and obesity therapies. The Danish drugmaker announced to spend more than 16 billion Danish kroner (€2.1 billion euros) starting in 2023 to expand its production site in Chartres, France, adding aseptic production and finished production processes and an extension of the current Quality Control Laboratory.

According to Novo Nordisk, the facility, which will more than double the site's footprint, will be designed as a multi-product facility to accommodate current and future processes.

“Our continued investments in our manufacturing sites across the globe demonstrate the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases,” said Henrik Wulff, Novo Nordisk’s executive vice president, Product Supply, Quality & IT.

The construction projects, Novo Nordisk said, are already underway and will be completed in stages between 2026 and 2028. The investment is expected to create more than 500 new jobs.

Company

Novo Nordisk A/S

Novo Allé
2880 Bagsværd
Denmark

Company contact

I am interested in:

an offer
a callback
detailed information

Your request

salutation first name last name

country phone email

Please note our data protection information for the contact form.

Virtual Event

Perfection Starts in the Tank

High Performance Food Production

On Demand | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

Interview

Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.